Clinical trial · Observational
A Study in Patients With Myasthenia Gravis in China
A Multicenter, Prospective Cohort Study in Patients With Myasthenia Gravis in China
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 19, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260919-000001
Summary
Brief summary (as posted)
This study is a multi-center, prospective cohort study designed to characterize current clinical practice, clinical and patient-reported outcomes (PROs), disease prognosis, treatment patterns and healthcare resource utilization for Chinese patients with myasthenia gravis (MG). This study will enroll patients with MG as diagnosed by physician. Approximately 1,200 MG patients are intended to be recruited from approximately 40 sites across majority of regions in China. The clinical and PROs included MGFA class, MGFA PIS, MG-ADL (Activities of Daily Living), QMG (Quantitative MG score), MG QOL-15R, EQ-5D etc. All MG patients enrolled will be followed up every 6 months until end of 2027.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myasthenia Gravis | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (12)
- measure
- Clinical outcome
- timeFrame
- Every 6 months up to 3 years
- description
- MGFA classification (e.g I, II, III, IV, V)
- measure
- Treatment method
- timeFrame
- Every 6 months up to 3 years
- description
- Targeted treatment methods (list of methods, including medication, immunoglobulin, plasma exchange, surgery etc. )
- measure
- Patient-reported outcome
- timeFrame
- Every 6 months up to 3 years
- description
- MG-Activities of Daily Living (MG-ADL, aggregated value in a scale, ranged 0- best to 24- worst)
- measure
- Clinical outcome
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 0 Years
Show eligibility criteria text
Inclusion Criteria: This study will enroll patients of all ages who are diagnosed with MG of all MGFA classifications by physicians. 1. Patients must have the following data to be enrolled in this study: * MGFA classification * MG-ADL score 2. MG patients or their legal guardians/representatives are able to sign the Informed Consent Form (ICF). Exclusion Criteria: 1. Patients aged ≥18 years with ocular myasthenia gravis (MGFA class I) lasting for more than 2 years; 2. Patients who are currently participating in an interventional clinical trial cannot be enrolled in this study.
References
Publications (0)
Data not yet available